USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
Antiretroviral Combinations Continue to Transform the Treatment Landscape
RELEASE DATE
03-Jul-2014
03-Jul-2014
REGION
Global
Global
Research Code: NE48-01-00-00-00
SKU: LS00129-GL-MR_16970
$3,950.00
Special Price $2,962.50 save 25 %
In stock
SKU
LS00129-GL-MR_16970
Description
This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.
Table of Contents
Key Market Developments since Q1 2013
Key Findings
Evolution of Standard of Care for HIV
Key Companies to Watch
Methodology and Scope
HIV Overview
HIV Overview (continued)
Prevalence of HIV/AIDS Globally and by Region
Market Segmentation
Market Segmentation (continued)
HIV/AIDS Antiretroviral Market—Competitive Landscape ofMarketed Products
HIV/AIDS Antiretroviral Market—Competitive Landscape ofProducts in Development
HIV/AIDS Antiretroviral Market—Product Launch and Patent Expiration Timeline
HIV/AIDS Antiretroviral Market—Major Phase 3 Ongoing Trials
HIV/AIDS Antiretroviral Market—Major Phase 3 Ongoing Trials (continued)
HIV/AIDS Antiretroviral Market—Recent Pivotal Trial Results
HIV/AIDS Antiretroviral Market—Recent Pivotal Trial Results (continued)
Marketed Product Synopsis—Multi-class FDC Products
Marketed Product Synopsis—Single-class FDC Products
Marketed Product Synopsis—Single-entity Products
Marketed Product Synopsis—Single-entity Products (continued)
Marketed Product Synopsis—Single-entity Products (continued)
Marketed Product Synopsis—Single-entity Products (continued)
Marketed Product Synopsis—Single-entity Products (continued)
Marketed Product Synopsis—Single-entity Products (continued)
Marketed Product Synopsis—Single-entity Products (continued)
Pipeline Synopsis—Late-stage Development Products
Pipeline Synopsis—Late-stage Development Products (continued)
Pipeline Synopsis—Late-stage Development Products (continued)
Pipeline Synopsis—Late-stage Development Products (continued)
Pipeline Synopsis—Late-stage Development Products (continued)
Pipeline Synopsis—Late-stage Development Products (continued)
Pipeline Synopsis—Early Clinical Development Products
Pipeline Synopsis—Early Development Products
Pipeline Synopsis—Early Development Products (continued)
Pipeline Synopsis—Early Development Products (continued)
Conclusions and Recommendations
Legal Disclaimer
Decision Support Database—Prevalence of HIV Infection
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
Decision Support Database—Prevalence of HIV Infection (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
plastic waste management market
biometric authentication market
This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.
| No Index | No |
|---|---|
| Podcast | No |
| Author | Randy Budros |
| WIP Number | NE48-01-00-00-00 |
| Is Prebook | No |